KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 129 filers reported holding KEROS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $851,451 | +43.8% | 26,708 | +81.3% | 0.00% | +50.0% |
| Q2 2023 | $592,012 | -22.7% | 14,734 | -17.9% | 0.00% | 0.0% |
| Q1 2023 | $765,995 | +3.4% | 17,939 | +16.3% | 0.00% | 0.0% |
| Q4 2022 | $740,805 | +36.9% | 15,427 | +7.2% | 0.00% | 0.0% |
| Q3 2022 | $541,000 | +40.2% | 14,390 | +2.9% | 0.00% | +100.0% |
| Q2 2022 | $386,000 | -60.3% | 13,986 | -21.9% | 0.00% | -50.0% |
| Q1 2022 | $973,000 | -7.1% | 17,900 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,047,000 | +47.9% | 17,900 | 0.0% | 0.00% | +100.0% |
| Q3 2021 | $708,000 | -6.8% | 17,900 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $760,000 | -31.0% | 17,900 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,102,000 | -13.7% | 17,900 | -1.1% | 0.00% | -33.3% |
| Q4 2020 | $1,277,000 | +195.6% | 18,100 | +61.6% | 0.00% | +200.0% |
| Q3 2020 | $432,000 | +2.9% | 11,200 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $420,000 | – | 11,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |